OverviewSuggest Edit

Olink Proteomics is a company providing products and services for human protein biomarker discovery. It offers a technique to identify actionable biomarkers that focuses on the human plasma proteome. The company provides cardiometabolic, cell regulation, cardiovascular, immune response, and other panels.

TypePublic
Founded2004
HQUppsala, SE
Websiteolink.com

Latest Updates

Employees (est.) (Dec 2020)214
Revenue (FY, 2020)$54.1 M(+30%)
Share Price (Sept 2021)$24.5(-4%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Olink

Jon Heimer

Jon Heimer

Chief Executive Officer
Oskar Hjelm

Oskar Hjelm

Chief Financial Officer
Rickard El Tarzi

Rickard El Tarzi

Chief Strategy Officer
Ida Grundberg

Ida Grundberg

Chief Scientific Officer
Fredrik Netzel

Fredrik Netzel

Chief Operating Officer
Carl Raimond

Carl Raimond

Chief Commercial Officer
Show more

Olink Office Locations

Olink has offices in Uppsala and Watertown
Uppsala, SE (HQ)
Uppsala Science Park
Uppsala, SE
Dag Hammarskjölds Väg 52B
Watertown, MA, US
65 Grove St
Show all (4)

Olink Financials and Metrics

Olink Revenue

Embed Graph
View revenue for all periods
Olink's revenue was reported to be $54.07 m in FY, 2020 which is a 29.7% increase from the previous period.
USD

Revenue (FY, 2020)

54.1m

Revenue growth (FY, 2019 - FY, 2020), %

29.7%

Gross profit (FY, 2020)

36.6m

Gross profit margin (FY, 2020), %

67.7%

Net income (FY, 2020)

(6.8m)

EBIT (FY, 2020)

(5.4m)

Market capitalization (21-Sept-2021)

2.9b

Closing stock price (21-Sept-2021)

24.5

Cash (31-Dec-2020)

8.7m

EV

3.0b
Olink's current market capitalization is $2.9 b.
USDFY, 2019FY, 2020

Revenue

41.7m54.1m

Revenue growth, %

30%

Cost of goods sold

13.0m17.5m

Gross profit

28.7m36.6m
USDFY, 2019FY, 2020

Cash

6.2m8.7m

Accounts Receivable

17.4m33.5m

Prepaid Expenses

1.0m1.5m

Inventories

11.9m20.8m
USDFY, 2019FY, 2020

Net Income

(17.9m)(6.8m)

Depreciation and Amortization

9.2m12.5m

Inventories

(2.8m)(6.0m)

Accounts Payable

224.0k3.7m
USDFY, 2019

Debt/Equity

0.5 x

Debt/Assets

0.3 x

Financial Leverage

1.7 x
Show all financial metrics

Olink Operating Metrics

Feb, 2021Mar, 2021

Customers Served

630

Patent Families

10

Patents

42

Publications

466
Show all operating metrics

Olink Acquisitions / Subsidiaries

Company NameDateDeal Size
Agrisera ABMay 07, 2020
Knilo BidCo AB
Olink Biotech (Shanghai) Co., Ltd
Olink Proteomics AB
Olink Proteomics B.V
Olink Proteomics GmbH
Olink Proteomics Holding AB
Olink Proteomics Inc.
Olink Proteomics KK
Olink Proteomics Ltd

Olink Revenue Breakdown

Embed Graph

Olink revenue breakdown by business segment: 27.3% from Kit, 63.6% from Services and 9.1% from Other

Olink revenue breakdown by geographic segment: 13.4% from Sweden, 51.4% from Americas, 27.6% from EMEA (excluding Sweden) and 7.6% from Other

Olink Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

SecurityScorecard logo

Olink Online and Social Media Presence

Embed Graph

Olink News and Updates

Olink to present at two upcoming investor conferences

UPPSALA, Sweden, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), today announced that Jon Heimer, CEO, and Oskar Hjelm, CFO, will participate in the following virtual investor conferences:

CellCarta expands its biomarker capabilities for clinical trials by adding Olink technology to its global services

UPPSALA, Sweden, Aug. 31, 2021 (GLOBE NEWSWIRE) -- CellCarta and Olink Proteomics AB announced today a strategic collaboration to offer Olink® Target 96 & Target 48 to pharmaceutical and biotech customers, advancing targeted protein biomarker quantification in clinical studies.

Olink: CORAL to use the Olink Proteomics platform to identify novel protein biomarkers and biological mechanisms for neurological diseases

UPPSALA, Sweden, July 27, 2021 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced that CORAL, a new collaborative community of scientists, will use the Olink Proteomics platform to identify novel protein biomarkers and biological mechanisms for neurological disease…

UK Biobank-PPP expands proteomics study of 53,000 participants to Olink Explore 3072

UPPSALA, Sweden, July 21, 2021 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced that the UK Biobank Pharma Proteomics Project (UKB-PPP Consortium) has decided to expand the ongoing proteomics study of 53,000 participants to the new Olink® Explore 3072 platform, providing a…

Olink Holding AB (publ) Announces Pricing of Public Offering of American Depositary Shares by Selling Shareholders

UPPSALA, Sweden, July 15, 2021 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) (“Olink” or the “Company”), today announced the pricing of a public offering of 7,500,000 American Depositary Shares, each representing one common share of the Company (the “ADSs”), to be sold by certain selli…

Olink enters into an agreement with deCODE genetics for early access to the Olink Explore 3072 Platform

UPPSALA, Sweden, July 13, 2021 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced that deCODE genetics, a global leader in analyzing and understanding the human genome, will have internal access to the Olink® Explore 3072 platform, comprised of approximately 3,000 high quali…
Show more

Olink Blogs

Olink Signature Q100 makes protein biomarker analysis easier than ever

At Olink we strive to always improve our platform and products to make it easier for you, the customer, to conduct your protein biomarker analysis. To this end we have collaborated with Fluidigm to make protein analysis simpler than ever when running our 48- and 96-plex Olink® Target pan…

Olink webinar October 22, 2021

“Detecting Cancer Biomarkers from Proteins in Liquid Biopsies” Please join us for this free Olink-sponsored, Drug Discovery News webinar, where Klaus Pantel MD, and Christoffer Gebhardt, MD from University Medical Center Hamburg-Eppendorf (UKE), German, and will discuss recent advances in liquid bio…

Can inflammation biomarkers classify different forms of diabetes?

Diabetes is a complex disease characterized by a combination of different and little understood, causes. The current classification system for the disease characterizes diabetes into three broad types: type 1 diabetes, type 2 diabetes, and gestational diabetes, but these three categories…

Introducing CORAL, a neurology research consortium using Olink data

In its mission to accelerate proteomics together, Olink encourages the advancement of science through comprehensive support of its customers in their own studies to achieve better insight into their areas of research. Sometimes, this may be achieved through collaboration with other sci…

How proteogenomics can improve drug discovery and development

With the advancement of available technologies in recent years, researchers are fast becoming aware of the advantages of using proteomics in their research to better understand human biology and disease and to drive pharmaceutical development towards new and improved therapies. Anders Mä…
Show more

Olink Frequently Asked Questions

  • When was Olink founded?

    Olink was founded in 2004.

  • Who are Olink key executives?

    Olink's key executives are Jon Heimer, Oskar Hjelm and Rickard El Tarzi.

  • How many employees does Olink have?

    Olink has 214 employees.

  • What is Olink revenue?

    Latest Olink annual revenue is $54.1 m.

  • What is Olink revenue per employee?

    Latest Olink revenue per employee is $252.7 k.

  • Who are Olink competitors?

    Competitors of Olink include Meso Scale Diagnostics, SomaLogic and Luminex.

  • Where is Olink headquarters?

    Olink headquarters is located at Uppsala Science Park, Uppsala.

  • Where are Olink offices?

    Olink has offices in Uppsala and Watertown.

  • How many offices does Olink have?

    Olink has 4 offices.